Edition:
United Kingdom

Mediwound Ltd (MDWD.OQ)

MDWD.OQ on NASDAQ Stock Exchange Global Market

4.70USD
13 Dec 2017
Change (% chg)

$-0.10 (-2.08%)
Prev Close
$4.80
Open
$4.75
Day's High
$4.75
Day's Low
$4.70
Volume
2,349
Avg. Vol
9,777
52-wk High
$8.25
52-wk Low
$4.20

Latest Key Developments (Source: Significant Developments)

MediWound Q3 loss per share $0.49
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - MediWound Ltd -:MediWound reports third quarter 2017 financial results.Q3 loss per share $0.49.Q3 revenue $740,000 versus I/B/E/S view $790,000.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.MediWound - ‍expected cash use to support operating activities in 2017 will remain toward lower end of co's guidance range for 2017 of $15 million -$17 million​.MediWound Ltd - ‍company may bear an additional $1.5 million expense to purchase shares of PolyHeal pursuant to district court ruling in Q4 of 2017​.  Full Article

Tel Aviv district court ordered Mediwound to purchase about $1.5 mln of PolyHeal shares
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Mediwound Ltd :Tel Aviv district court ordered Mediwound to purchase approximately $1.5 million of PolyHeal shares; Mediwound weighing an appeal.‍Continues to evaluate ruling and its legal and accounting implications and company's options, including a potential appeal​.Court ordered that co is obligated to purchases shares of 3 shareholders of PolyHeal pursuant to claim made by such PolyHeal shareholders​.  Full Article

MediWound appoints Mr. Stephen T. Wills as chairman
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Mediwound Ltd :MediWound appoints Mr. Stephen T. Wills as chairman to its Board of Directors.Mediwound Ltd - ‍ appointment of Stephen T. Wills as chairman upon resignation of Aharon Yaari from Board​.Mediwound Ltd - ‍ Wills currently serves as Chief Financial Officer and Chief Operating Officer of Palatin Technologies​.  Full Article

MediWound Ltd announces new distribution agreement with Holy Stone Healthcare for NexoBrid
Monday, 16 Oct 2017 

Oct 16 (Reuters) - MediWound Ltd :MediWound Ltd - ‍ announced an agreement with Holy Stone Healthcare, co for distribution of Nexobrid in Taiwan for treatment of severe burns​.  Full Article

Mediwound reports final positive results of phase 2 clinical trial of Escharex
Tuesday, 31 Jan 2017 

Mediwound Ltd : Mediwound reports final positive results of phase 2 clinical trial of escharex for the debridement of chronic and hard-to-heal wounds . Based on final clinical study report, phase 2 clinical trial of escharex met its statistically-powered primary endpoint 2 .Mediwound ltd- expect to complete second cohort of phase 2 study and to report top-line data in mid-2017.  Full Article

Mediwound posts Q2 loss per share of $0.34
Thursday, 28 Jul 2016 

Mediwound Ltd : Mediwound Ltd says during 2016 co will continue to invest primarily in its sales and marketing activities in Europe to advance adoption of Nexobrid . Mediwound reports second quarter 2016 financial results . Q2 loss per share $0.34 . Q2 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S .Cash use for FY is expected to be $18 million to $20 million, lower than company's previous forecast which was in range of $20 million to $22 million.  Full Article

Mediwound Ltd meets primary endpoint in second phase 2 clinical trial for the debridement of chronic and hard-to-heal wounds
Tuesday, 2 Feb 2016 

Mediwound Ltd:Meets primary endpoint in second phase 2 clinical trial for the debridement of chronic and hard-to-heal wounds.Says plans to submit the final data to the U.S. food and drug administration (FDA) in the second half of 2016.Says planned three-month follow-up is ongoing; expects the analysis of the complete dataset to be finalized in mid-2016.  Full Article

Mediwound Ltd expands Latin American distribution of Nexobrid
Thursday, 21 Jan 2016 

Mediwound Ltd:Mediwound expands Latin American distribution of nexobrid through agreement with avalon pharmaceutical s.a.Agreement granting Avalon Pharmaceutical S.A exclusive rights to market and distribute nexobrid in Colombia, Peru, Chile, ecuador,panama.Sales of nexobrid in new latam territories will commence after receipt of local regulatory approvals.  Full Article

BRIEF-MediWound Q3 loss per share $0.49

* Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S